Ibnsina Pharma results, Q4 2025
Net profit, assets, equity and cash flow for Q4 2025, against the same period a year earlier, from the published financial statements.
Net profit292 millionEGP · +40.4% vs the same period a year earlier
In short
- Ibnsina Pharma's net profit for Q4 2025 was about 292 million EGP, up +40.4% from 208 million EGP in Q4 2024.
Key lines against the same period a year earlier
This periodQ4 2024Change
Net profit292 million208 million+40.4%
Gross profit1.62 billion1.42 billion+14.1%
Total assets—28.64 billion—
Total liabilities—26.61 billion—
Shareholders' equity—2.03 billion—
Total liabilities and equity—28.64 billion—
Operating cash flow—-1.1 billion—
Investing cash flow—-113 million—
Financing cash flow—1.13 billion—
Net change in cash—-79.08 million—
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Ibnsina Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy